Bluebird, Celgene add a promising chapter to their success story with BCMA-targeting CAR-T — and turn it around with investors
CHICAGO — Right now at Celgene $CELG and bluebird $BLUE, it’s all about the KarMMa — and they’re looking to burnish theirs at ASCO.
In a peek at the first batch of highly promising data to hit at ASCO, investigators are amplifying evidence of positive objective response rates for the drug, with an encouraging progression-free survival rate of close to a year to illustrate its potential durability for patients with far advanced cases of multiple myeloma — particularly in the high-dose group. And it all looks tailor made for priority handling at the FDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.